Public Comments to Agencies
Comments to FDA on Labeling for Biosimilar Products
May 31, 2016 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852. Re: Docket No. FDA-2016-D-0643 “Labeling for Biosimilar Products; Draft Guidance for Industry”
FCC Comments on Protecting the Privacy of Customers of Broadband and Other Telecommunications Services
[PDF Download]
Public Comments on FCC AllVid Proposal
Sections: [Introduction] | [Government Technology Mandates] [Market Competition] | [Abrogation of Intellectual Property Rights]
Comments to the FCC regarding the Regulatory Status of Mobile Messaging Services (WT Docket No. 08-7)
Before the FEDERAL COMMUNICATIONS COMMISSION Washington, D.C. 20554 In the matter of
CCAGW Sends Letter to CMS Admin. Marilyn Tavenner Regarding Part D Draft Guidance
October 24, 2014 The Honorable Marilyn Tavenner Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services 200 Independence Avenue Washington, D.C. 20201 Dear Administrator Tavenner,
Comments to FDA on Biosimilars
Margaret A. Hamburg, M.D. Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 Dear Commissioner Hamburg,
